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The scientific discovery of a range of genetic mutations has meant that people with a 
strong family history of cancer can find out whether they are at risk of developing 
cancer well before they have any symptoms. Genetic testing has opened up the 
possibility for otherwise healthy mutation carriers to access prophylactic treatments in 
order to minimise their risk. These include surgery to remove at-risk body parts, 
treatment with cancer drugs, medical surveillance strategies, self-surveillance and 
change in lifestyle. Clinical experience to date has shown considerable resistance to 
the uptake of medical preventative measures despite their promise of risk reduction. 
This paper provides a summary review of the available literature on the medical, 
psychological, counselling and social aspects of genetic testing and the use of risk-
reducing treatments by people who have been diagnosed with a genetic predisposition 
to cancer. It acknowledges what has been learned from these approaches but points to 
the similarity of the philosophical underpinnings of most of the research. It concludes 
by tentatively making some suggestions, informed by the literature, about new 
directions for guiding our understanding the genetically at risk and the factors that 
influence their decision-making. 
Introduction 
The discovery of a range of genetic mutations has meant that people with a strong 
family history of cancer can find out whether they are at risk of developing cancer 
well before they have any symptoms.2 Testing can determine if an individual is more 
susceptible than others in the population to developing the cancer. The patterns of 
cancer onset, however, are not straightforward; for example, in Australia among 
carriers of the BRCA1 and BRCA2 gene mutations, the cumulative lifetime risk is 50-
60 per cent for developing breast cancer and 20-40 per cent for ovarian cancer.3 
Although there is no certainty they will develop cancer, ‘at risk’ people are offered a 
range of preventative medical risk management options which themselves are 
potentially harmful. For example, meta-analyses of studies on carriers of BRCA1 and 
BRAC2 have shown post-operative psychological and physical morbidity after 
prophylactic surgery4 and a small probability of serious side-effects from 
chemoprevention, including uterine cancer and death from blood clots.5 The most 
effective medical risk reduction strategy is deemed to be the surgical removal of 
currently unaffected but cancer-susceptible body parts, such as breasts or ovaries, 
which can lower the person’s risk of getting breast or ovarian cancer to below that of 
the general population.6 Other medical options offered are risk-reducing drug therapy 
or chemoprevention (involving drugs such as tamoxifen or raloxifine) or surveillance 
strategies, which include regular radiographic imaging such as mammography, 
magnetic resonance imaging (MRI), ultrasound (for ovarian surveillance) and regular 
clinical examination.7 Non-medical strategies include routine self-examination and 
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attention to lifestyle factors such as weight and diet management, though these are 
viewed as less than optimal.  
 
For those found to have a genetic predisposition to breast and ovarian cancers, 
preventative or prophylactic surgery is seen to be the best form of risk management, 
although not a guaranteed solution, while surveillance techniques are thought to be 
less successful at early detection, particularly in young women whose denser breast 
tissue tends to compromise cancer detection by mammography.8  
 
According to the medical literature, the discovery of a cancer gene mutation is 
predictive of cancer; it has no immediate effect on physical health and not all people 
who have the genetic mutation go on to develop cancer. In particular, people 
identified with a genetic mutation which is predictive of cancer can be offered 
preventative treatment. However, clinical experience to date has shown considerable 
resistance to the uptake of medical preventative measures despite their promise of risk 
reduction.9  
 
The aim of this paper is to provide a summary review of the available literature on the 
medical, psychological, counselling and social aspects of genetic testing for breast and 
ovarian cancer and to outline what is known about the use of risk-reducing treatments 
by people who have been diagnosed with a genetic predisposition to cancer. While 
there is a wealth of information about the clinical experience of those genetically at 
risk of cancer and the reasons for the treatment choices they make, an understanding 
of their decision-making outside of the clinic has been much less explored. This paper 
reviews the literature around decision-making on medical treatment options, including 
surgery, drug therapy (chemoprevention) and medical surveillance (MRI, ultrasound 
and mammography). It also explores literature that moves through phenomenological 
accounts of the experience of being genetically at risk of disease to the accounts of the 
broader social changes that might impact on people’s health decision-making. While 
there is much to be learnt from the literature to date, its focus on informed decision-
making through non-directive counselling in the clinic may overlook factors that 
contribute to quite active decisions to resist medical treatment that are grounded in the 
conditions of the lives of people who are genetically at risk of cancer.  
Research on those at risk of genetic cancers 
Although genetic testing is available for more than 1000 inherited disorders, most 
research on genetic cancer predisposition and uptake of treatment options has been 
conducted on breast and ovarian cancer10 because awareness has been raised by 
institutionalised population screening programmes. Fewer studies have been 
conducted on people who have a predisposition to other forms of cancer such as 
bowel and prostate cancers.11 This paper will focus on those who are known through 
genetic testing to carry the BRACA1 and/or the BRCA2 gene mutation/s, though the 
issues raised are likely to have broader application to those identified with a range of 
other genetic cancer mutations.  
 
Overall, studies focus mainly on psychological, clinical and counselling aspects of 
genetic testing, with a smaller but increasing number concerned with the use of risk-
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reducing treatments by people who have been diagnosed with a genetic predisposition 
to cancer. These studies can be divided into three broad but overlapping categories: 
those that explore attitudes to, or intention to comply with, recommended treatment;12 
those that have investigated patterns of surveillance behaviours and rates of 
prophylactic surgery uptake following genetic mutation testing;13 and, those that 
investigate factors contributing to decision-making about treatment options.14 A 
further two categories include social science research which focuses on the experience 
of patients and families coping with a genetic disease itself15 and those studies that 
take a broader socio-cultural approach to the importance of the body in consumer 
culture and a consumerist approach to risk and risk assessment in relation to the 
medicine and medical technologies.16 Comparatively little is known about how the 
larger group of mutation carriers who eschew all forms of medical treatment make 
sense of their risk in the broader context of their lives, the complicated and daunting 
decisions that they have to make and the reasons why they decide against medical 
treatment options.17  
Clinical studies: Levels of treatment uptake and compliance rates 
Most studies report relatively low levels of intention to undergo prophylactic 
surgeries, with bilateral ovarian removal (salpingo-oophorectomy) much more 
acceptable to women than breast removal (mastectomy).18 When it comes to actual 
behaviours of carriers of genetic mutations, the patterns of prophylactic surgery and 
surveillance are similar to studies of intentionality. Claes and colleagues,19 in a one-
year follow-up after a mutation positive test, found that 9 per cent of women had had 
a prophylactic bilateral mastectomy while 75 per cent had had a bilateral 
oophorectomy. Meijers-Heijboer et al’s study of 682 mutation carriers found much 
higher rates of bilateral mastectomy (51 per cent) and oophorectomy (64 per cent) in 
young women aged 30-44.20 A smaller study found that a majority of carriers did not 
choose surgery (only 3 per cent and 13 per cent respectively) but 68 per cent had 
regular mammography screening.21 Similarly, Botkin et al’s study showed a zero and 
46 per cent uptake rate respectively of surgery and 82 per cent mammography 
compliance.22 Evans and colleagues found that 61 per cent of eligible women opted 
for MRI screening23 while Metcalfe et al reported low levels of chemoprevention 
uptake (12 per cent tamoxifen and 10 per cent raloxifene).24 More recent studies have 
found variation in the uptake rates of risk-reducing surgery contingent on time from 
gene test to follow-up, with higher overall rates, especially among younger women 
who tend to delay bilateral removal of ovaries until family completion.25 In addition, 
variation in uptake depends on country of study, with the United States having the 
highest rates of prophylactic bilateral mastectomy (36.3 per cent).26 A review study 
examining the evidence for prophylactic treatments pointed out that all these studies 
are retrospective and short-term follow-up prospective cohort studies that fall well 
short of the rigour of randomized control trials and thus provide insufficient 
justification for making irreversible decisions about radical prophylactic treatments.27  
 
In summary, rates of uptake of preventative surgery are uneven, indicating that 
programmes have different levels of success in enrolling the genetically at risk in 
preventative treatments. Despite this, even those programmes with the highest rates of 
treatment uptake show a high number of mutation-positive people rejecting 
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prophylactic surgery and an even higher number refusing chemoprevention. While 
surveillance techniques are less efficacious, they appear to be the preferred treatment 
choice for mutation positive-people who remain under the ‘medical gaze’.28  
Psychological and counselling studies: decision-making around treatment 
options 
Most studies on people who are genetically at risk of cancer have been undertaken 
with clinical samples and focus on psychological, clinical and counselling aspects of 
genetic testing. The majority are from a medical science and psychological 
perspective and they generally show the benefits to people of knowing and 
understanding their genetic risk status in relation to cancer.29 Perhaps unsurprisingly, 
given the clinical setting of the studies, they also show that predictive genetic testing 
itself does not necessarily have major adverse psychological outcomes.30 On the other 
hand, studies on familial genetic testing show that a substantial number of first-degree 
relatives, who are likely to receive their information in a non-clinical context, do not 
follow up offers to find out about cancer mutation status and do not adhere to 
surveillance guidelines.31 A subsection of these studies investigate factors that 
contribute to decision-making around risk-reducing treatment options. Reasons given 
for non-uptake of preventative measures are reported to be related to personality 
factors such as ‘psychological vulnerability’ and ‘psychological functioning,’ 
including feelings of guilt about having and passing on a defective gene, and distress, 
anxiety and depression during and after genetic testing.32  
 
In terms of understanding why people opt for prophylactic treatment, anxiety about 
cancer risk itself has been found to be more likely to motivate women to seek 
prophylactic bilateral mastectomy than actual level of risk.33 Counselling studies also 
focus on ways of reducing ‘cancer worry’ and improving information provision about 
risk, something that is often quite complex to convey in lay terms. The effectiveness 
of risk communication has also been assessed, with studies showing that perception of 
risk is more accurate after counselling, and that individual differences as well as 
variation in social and environmental factors need to be taken into consideration.34 
Genetic counselling focuses on interpretation of risk factors, education about 
‘inheritance, testing, management, prevention, resources and research’, and 
counselling to promote informed choice about treatment options.35 These, though, are 
all traditional medical options: surgery, drugs, or surveillance technologies that can be 
provided in the clinic. Mandated genetic counselling is itself underpinned by an 
assumption that health decisions are made on the basis of objective knowledge about 
risk and treatment options. In this view, rejection of medical treatment is seen to be 
based on a ‘knowledge deficit’ which can be rectified, and acceptability increased, 
with education and the dissemination of accurate and objective information.36 While 
the client-led non-directive genetic counselling model differs significantly from the 
traditional hierarchical medical model in terms of informed and autonomous decision-
making, the range of options from which a decision is to be reached remain medical 
alternatives. Although immediate familial contexts are taken into consideration in the 
counselling model, the broader socio-cultural factors that may contribute to decision-
making are not. 
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The focus on individual psychological morbidity and its relief through effective 
counselling overlooks both the overwhelming nature of the information itself and 
normality of people’s responses to it. It also overlooks some of the more complex 
responses that gene mutation carriers might have. Butow and her colleagues refer to 
individual responses as “somatic distress”,37 promising to extend analysis beyond an 
examination of behavioural responses to the embodied experience of being identified 
as a mutation carrier. While this approach implies a more complex visceral process, 
around the embodied experience of being genetically at risk, it is left unexplained. 
However, Barsky provides an explanation of somatic symptoms which seems to imply 
a condition otherwise known as ‘anxiety’ or ‘panic attack,’ wherein the sufferer has 
awareness of bodily changes but these are not evidenced upon physical examination.38 
Similarly, other studies point to (but do not expand on) factors such as ‘emotional 
responses’ that impact on levels of ‘cancer worry’.39 Several clinical studies have 
sought to understand the emotional impact on women who have undergone 
prophylactic surgery to eliminate cancer risk.40 Those who opted for surgical methods 
reported more distress about their mutation carrier status than those who decided on 
medical surveillance and, in both the short and longer term, although their cancer risk 
worry was significantly reduced, their level of anxiety remained higher than for the 
surveillance group.41 In other words, predictive genetic knowledge appears to be more 
worrisome for those with a propensity towards anxiety in general.  
Social science approaches: The experience of being genetically at risk 
Most of the phenomenological research into meaning making from a patient 
perspective focuses on patients’ and families’ experiences of coping with a genetic 
disease itself.42 These studies engage with lay models of genetic inheritance and 
provide contextual explanations for understanding how people make sense of the 
multifactoral nature of genetic disease causation.43 While they provide important 
insights into the life-worlds of at-risk individuals, these experiential studies generally 
maintain the clinical focus of the medical, psychological and counselling approaches. 
The experiential dimension, by necessity, contextualizes the individual within the 
clinic which, as Kerr argues, tends to invoke and reinforce the passive and dependent 
patient role of traditional biomedicine, while positioning healthy mutation carriers and 
other pre-symptomatic family members as patients ‘waiting to become ill’.44  
 
Other studies report on lay understandings of genetic inheritance and how people 
make sense of their own genetic risk through a range of heuristic strategies, family 
storytelling and interpretation of risk factors according to emotional and age closeness 
to a cancer affected relative.45 In those who had a positive test result, familial risk 
itself was found to be mediated by strong moral notions of responsibility to the family 
to inform and disseminate information about carrier status and of ‘doing the right 
thing’ in relation to compliance with treatment regimens.46 Disclosure of risk was also 
reported to be a gendered responsibility falling disproportionally on women.47 Other 
studies on genetic risk focus on how people’s perceptions of risk change over time 
and become more or less salient at different stages of their lives.48 Some of these 
studies make parallels between living with the knowledge of being genetically at risk 
of disease and the experience of living with a chronic illness. Despite the uncertainty 
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around genetic status for those with a family history of cancer and those for whom the 
genetic test is not definitive, they report that being at-risk of genetic disease has a 
similar impact on self identity as does having chronic illness. It is experienced as 
‘biographical disruption’ or a profound disturbance in one’s sense of self, one’s place 
in the world and one’s relationship to others.49 Even though most of these studies 
provide important insight into the experience of genetic risk and position the at-risk 
individual in the context of their immediate familial and social interactions, they 
remain conceptually aligned with the genre of clinic-based studies that tend to 
exaggerate the place of risk in people’s lives.50 By locating their experience in the 
potentiality of biological risks, rather than in the broader structural conditions of their 
lives, they give only partial perspective on the individual experience of hereditary 
cancer risk.  
The wider socio-cultural context of predictive genetic testing 
Recent risk studies link individual risk and risk awareness to the sociological 
literature on ‘risk society’ and a generalised appreciation of the multifarious sources 
of danger and risk in contemporary life that are seen to threaten health and safety, of 
which genetic risk is one.51 Genetic risk communication itself solidifies for 
individuals and their families otherwise quiescent health risks which potentially 
threaten everyone, given the multitude of mutations that may exist in a family’s gene 
pool.52 Engagement with the discourse of the genetic clinic, which constructs 
mutation carriers as responsible for managing their own health risks, not only 
heightens risk awareness but also the burden of genetic knowledge.53 The genetically 
at risk are charged with the duty to acquire genetic risk information as well as to 
disseminate and communicate risk status to family members.54 The burden of genetic 
knowledge extends also to those with familial risk even where a test outcome is 
inconclusive, because disease-free individuals who remain uncertain about their 
mutation status are left to engage in a range of regular, ongoing and precautionary 
medical surveillance activities .55 Once diagnosed with a genetic mutation, carriers 
take on the collective fear of cancer and, though they are still cancer free, the threat 
becomes immanent and they may want to have removed the potentially affected body 
part, which is now recast as dangerous.56 Discursively, there is a broader moral and 
social imperative to engage in curative, preventative actions which may be more 
dangerous and disfiguring than the potential disease they seek to eliminate.57  
 
In their study of the genetically at risk for ovarian cancer, Hallowell and Lawton 
found that, while the decision to undergo prophylactic surgery provided participants 
with a sense of agency to achieve a risk-free body, the removal of (healthy) ovaries as 
a ‘cure’ also incurred emotional, material and interpersonal losses to identity, body 
and sense of self.58 In one clinical study, researchers asked women about body image 
and intimate relationships following prophylactic mastectomy or oophorectomy.59 
They found that surgery could have serious negative outcomes for a woman’s self 
image, self esteem and physical and emotional well-being. While it seems to be the 
best option from a clinical viewpoint, prophylactic mastectomy is the least acceptable 
for women themselves.60 Seen in socio-cultural context, the centrality of the body and 
its exteriority have become important to self definitions and expressions of the self, so 
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radical surgery and its side-effects challenge body image, feelings of well-being, 
personal identity, and sexual relationships.61  
 
Much research consistently overlooks the substantial changes that have occurred in 
patterns of health consumption, including the pre-eminence given to having a healthy 
body. In contemporary consumer culture, continual efforts are made by individuals to 
maintain, shape and perfect the body through routines of diet, exercise and 
preservation of well-being that go beyond simply being healthy.62 The body has thus 
become a key site of vigilance through self-surveillance and self-care.63 But this 
activity is confounded by knowledge of the embodied self as the at-risk mutation 
carrier who is potentially unhealthy. Having an inherited predisposition to cancer is at 
odds with the hitherto exterior, experiential and healthy body. Within a medical 
framework, the genetically at risk are expected to consume treatments that interrupt 
their continual and ongoing body work. What this means is that, rather than simply 
being non-compliant or resisting medical intervention, those at risk of disease may 
actively and rationally choose not to engage in prophylactic treatment measures.  
 
The 21st century has seen the emergence of a new, informed medical consumer who 
has greater access to health information through the internet and the bombardment of 
public health messages.64 This informed medical consumer is empowered to enter the 
clinical encounter largely on her own terms, thus deconstructing the traditional 
‘passive patient’ role, which was characterized by unquestioned practitioner authority 
over patients.65 In the context of predictive genetic testing, the client (who is not a 
physically sick patient) is defined as suitable for certain medically prescribed 
preventative treatment measures. While the traditional 'doctor knows best' idea 
absolved the patient from responsibility for illness and its management, the ideas of 
self-care and health maintenance now make the lay person, rather than the 
professional, responsible for health decision-making.66 This has resulted in the co-
construction of new dialogue between doctor and patient in which the 
patient/consumer seeks to maximize the value of medical services by actively 
engaging with, assessing and challenging expert medical knowledge, while 
consuming or rejecting medical services.67 What this may mean is that, for the 
genetically at risk, the decision not to engage with medical treatment options, may 
very well be an active and informed choice rather than non-compliance or a failure to 
understand the benefits of prophylactic measures.  
 
Additionally, given the low client acceptability of prophylactic surgery and 
chemoprevention68 and the low sensitivity of the test, which detects only 25 per cent 
of those mutations with a hereditary basis, Boenick69 suggests that genetic testing 
should first be carried out on already ill or symptomatic women and only after 
mutation status is identified as familial should testing be offered to non-symptomatic 
family members. This would narrow the target population and increase the 
predictability of the test, thus avoiding the burden on healthy individuals who do not 
have a definitive test outcome and are left with having to engage in a range of 
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A more positive view of health consumer choice in the face of genetic knowledge is 
put forward by Novas and Rose, who argue that the new genetics has seen “the 
reshaping of personhood,” with the genetically at risk assuming responsibility and 
achieving their full potential within “new communities of obligation and 
identification”.70 From their study, they contend that people who are genetically at 
risk do not simply accept genetic diagnoses as constitutive of their entire identity. 
Rather, they develop strategies that make sense in their lives at any particular time. In 
the context of people’s everyday lives, negative responses to being at risk can be 
subverted and actively resisted. Genetic diagnoses therefore need to be understood in 
collective contexts where family, social and cultural responses can and do shape 
interpretations in a multiplicity of ways.71 
 
Broader socio-cultural approaches demonstrate both the complexities and uncertainty 
of predictive genetic testing and the decision-making processes faced by those known 
to carry a genetic mutation that puts them at risk of cancer. They open up the 
possibility of understanding the genetically at-risk from a different stance from the 
clinical, by assessing the individual and social acceptability of predictive genetic 
testing and treatment based on probabilistic information. Although some of these 
studies were conducted within clinical settings, they are philosophically informed by a 
paradigm that takes understanding outside a purely medical framework. A medical 
paradigm is underpinned by assumptions that limit the possibility of better 
understanding the motivations and decision-making processes of those who are 
genetically at risk. In particular, medical, clinical and counselling, as well as some 
social, research operates within the closed conceptual system of traditional 
biomedicine wherein the discovery of disease is followed by a curative intervention. 
So, once a mutation (or even its possibility) is identified, the option of not taking up 
treatment is foreclosed even if the gene has not expressed and the person is cancer 
free.  
 
The final conceptual hurdle to an appreciation of the dynamics of consumer 
understanding and use of predicative genetic testing and consequent (non)uptake of 
medical treatment options rests with the epochal change in the nature of medical 
practice itself, from curative to predictive medicine.72 A new era in the history of 
medical practice has heralded a move from certainty about health and illness and 
curing sick bodies to the prediction of illness and probability of future disease. While 
the shift from curative to predictive medicine has been made at a conceptual level, 
clinical practitioners remain caught within the curative model when it comes to acting 
upon predictive information. There is a mismatch between what is known about health 
and disease and what can be done about it. On the one hand, clinicians have extremely 
sophisticated techniques to identify potential disease at a molecular level, providing 
information that might lead to preventative measures to promote health and well-
being. On the other, currently available treatment options are borrowed from curative 
medicine and are somewhat blunt instruments for dealing with healthy bodies 
potentially at risk of cancer.  
 
These theoretical constructs highlight the need to explore consumer acceptability of 
medical treatment in the context of differential understandings of the healthy body; 
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that is the healthy, ‘lived’ and somatic or experienced body versus the body deemed to 
be medically healthy (cancer-free or cancer-risk minimised). Future research needs to 
take as a starting point an understanding that the subjective perceptions of those 
genetically at risk are likely to be based on their active engagement with a complex 
social world and a broader matrix of social relations. Such an approach opens up the 
possibility of exploring the cultural, personal, historical and social factors that 
contribute to the ways in which the genetically at risk understand, engage with and 
resist knowledge about genetic risk. Furthermore, understanding quality of life issues 
from the perspective of those genetically at risk will inform ways by which predictive 
genetic knowledge can be better used in the service of preventative healthcare. The 
World Health Organisation, in its promotion of positive health and the pursuit of 
wellness, counsels the “appropriate” use of technologies. Best practice strategies for 
testing and treatment need to evaluate the ethical and psychosocial issues against the 
benefits of the risk-reduction treatments of traditional biomedicine. Finally, the high 
economic cost of genetic testing, genetic counselling and medical prevention options 
necessitates a thorough understanding of individual, family and population opinions 
and needs in relation to predictive genetic testing.  
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